Back to mobile site

RBC on Pfizer (PFE): 'Litigation overhang cleared'

April 28, 2026 9:46 AM EDT Send to a Friend
RBC Capital analyst Trung Huynh reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).The analyst comments "Our ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login